In short
Clinical trials investigating ALKYLATING AGENTS are studying treatment options for people with myelofibrosis, especially those with intermediate-2 or high-risk disease. The main goal is to compare outcomes such as overall survival and see how well current treatment choices work in patients whose disease is not responding to JAK-inhibitor treatment.
Key points
- Clinical trials investigating ALKYLATING AGENTS in the provided data focus on myelofibrosis, a blood cancer that affects the bone marrow. The listed study is a Phase 3 interventional trial in people with intermediate-2 or high-risk disease. It looks at patients whose disease is relapsed or refractory after JAK-inhibitor treatment, meaning the disease has returned or is not responding. The main endpoint is overall survival, which measures how long participants live after randomization. The trial plans to enroll 354 people and is currently authorised.
Trial overview
The provided trial data include one authorised interventional study, which means researchers assign treatments and then measure the results in patients. The study is in myelofibrosis, a blood cancer that affects the bone marrow and can cause serious illness.
The trial title says it compares current available therapies with imetelstat for people with intermediate-2 or high-risk myelofibrosis who are not responding to JAK-inhibitor treatment. The brief summary says the main goal is to compare overall survival in people with relapsed or refractory disease.
Who is being studied
This study is for people with intermediate-2 or high-risk myelofibrosis. These risk groups describe more serious disease, so the trial focuses on patients who may need stronger treatment options.
The study also includes patients whose disease is relapsed or refractory after JAK-inhibitor treatment. Relapsed means the disease has returned, and refractory means it is not responding to treatment.
What the study compares
The trial compares current available therapies with imetelstat. This kind of comparison helps researchers see whether one treatment approach leads to better outcomes than the other.
The intervention list shows imetelstat given intravenously, which means through a vein. The data do not provide further details about the other treatment options, only that they are current available therapies.
Study phase and size
This is a Phase 3 trial. Phase 3 studies are later-stage trials that usually compare treatments in a larger group of patients.
The planned enrollment is 354 participants. A study of this size can help researchers compare results more reliably across treatment groups.
Main endpoint
The primary outcome is overall survival. Overall survival means the time from randomization to death from any cause.
This endpoint is important because it shows whether one treatment strategy helps people live longer than another. In this study, researchers are using overall survival to judge the main benefit of treatment.
What the results may mean for patients
From the trial data, the main question is whether the study treatment approach can improve survival for people with difficult-to-treat myelofibrosis. The study is focused on patients whose disease has not responded well to JAK-inhibitor treatment, so it targets a group with limited options.
The trial is authorised, which means it has been approved to move forward. Because the study is still a clinical trial, its purpose is to test and compare outcomes rather than to give a final answer about treatment success.